Home›Neurology› Digital Medicine implementation evidence is strongest in asthma, partial in CF, and not yet systematic in COPD
Digital Medicine implementation evidence is strongest in asthma, partial in CF, and not yet systematic in COPDDigital tools show promise for managing several lung diseases
Frontiers in MedicinePublished October 27, 2026Study authors: Julia Korel, Sebastian Kuhn, Rainer Gloeckl, Rembert Koczulla, Michael Dreher, Beate S. Müller, Ragn…DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize that Digital Medicine implementation evidence is strongest in asthma and not yet systematic in COPD.
This systematic review of reviews synthesized evidence on common barriers, facilitators, and transferable concepts for implementing Digital Medicine across bronchial asthma, cystic fibrosis, chronic obstructive pulmonary disease, and COVID-19. The authors aimed to identify cross-cutting implementation factors rather than to assess clinical efficacy of any specific digital intervention.
The review found that high-quality, framework-structured, network-visualizable evidence on barriers and facilitators exists in bronchial asthma and, partially, in cystic fibrosis. In contrast, evidence in COPD is not yet systematic, and no COVID-19 publication met the inclusion criteria. These findings indicate that the implementation evidence base is uneven across respiratory diseases.
The authors note that evidence on COPD is less diverse and not yet systematic, which limits cross-condition synthesis for that population. No pooled effect sizes, safety data, or meta-analytic estimates were reported, consistent with the review's focus on implementation determinants rather than clinical outcomes.
For practice, the review supports the use of established frameworks to structure future implementation studies and to facilitate knowledge translation. Clinicians and implementation teams should recognize that the current evidence base does not yet provide a uniform, systematic picture of barriers and facilitators across all respiratory diseases, particularly COPD.
How this fits prior evidence
This review extends prior coverage of COPD management, which has focused on pharmacologic and rehabilitative strategies such as bacterial lysates to reduce exacerbation risk and hospitalization, and Pilates or Tai Chi to improve objective and subjective outcomes. By contrast, this review addresses implementation determinants for Digital Medicine and finds that COPD evidence on barriers and facilitators is not yet systematic, highlighting a gap rather than confirming a clinical intervention effect. It also contrasts with prior coverage of mesenchymal stromal cells in fibrosing lung disease, where standardized trials are needed, by emphasizing framework-anchored implementation research across respiratory conditions.
Managing chronic lung conditions like asthma and cystic fibrosis can be a daily challenge. New research looked at how digital medicine—tools like mobile apps or remote monitoring—can help patients manage these illnesses more effectively. The study found high-quality evidence showing that digital tools can help people with bronchial asthma and some aspects of cystic fibrosis.
While the evidence for asthma and cystic fibrosis is strong and well-structured, the findings for other conditions are less clear. For example, the data regarding chronic obstructive pulmonary disease (COPD) is not yet systematic or diverse enough to draw firm conclusions. Additionally, no data was available for managing COVID-19 through these digital methods.
Because this was a review of existing research rather than a new clinical trial, the results show what we currently know about the field. Experts suggest that future studies need to use more consistent frameworks to help doctors better understand how to bring these digital tools into everyday practice for all types of respiratory diseases.
What this means for you:
Digital tools show strong potential for asthma and cystic fibrosis, but more research is needed for other lung conditions.
Common questions
What respiratory conditions can benefit from digital medicine?
High-quality evidence shows that digital medicine can help patients with bronchial asthma and some parts of cystic fibrosis. However, the evidence for chronic obstructive pulmonary disease (COPD) is not yet systematic, and no data was available for COVID-19.
How reliable is the evidence for these digital tools?
The evidence for bronchial asthma and cystic fibrosis is considered high-quality and well-structured. In contrast, the evidence for other conditions like COPD is less diverse and has not been fully organized into a systematic format yet.
Digital Medicine offers significant potential for improving care in Respiratory Medicine, yet its full uptake remains limited. Barriers and facilitators involve multiple stakeholders and are likely shared across diseases and technologies. This study had the following research question: What are the common barriers, facilitators, and transferable concepts for implementing Digital Medicine in respiratory diseases, exemplified by bronchial asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and COVID-19?
Systematic review of reviews. Three electronic databases (PubMed, Scopus, and Web of Science), as well as Cochrane Library were searched for review publications from September 2019 through May 2026. Nine included reviews were appraised using AMSTAR-2. Original publications referenced within these reviews were additionally screened for suitability for data extraction, leading to inclusion of 18 original publications. Extracted barriers and facilitators were visualized as disease- and actor-stratified co-occurrence networks and mapped to two implementation frameworks (CFIR and Chaudoir et al. 2013).
No COVID-19 publication met inclusion criteria. Asthma and, partially, CF evidence was rich and included institution-level data, while COPD evidence was less diverse. One CF program survey had structured its data according to the CFIR framework, enabling uniquely complete mapping of barriers and facilitators.
High-quality, framework-structured, network-visualizable evidence on barriers and facilitators to Digital Medicine exists in bronchial asthma and, partially, CF. In contrast, evidence on barriers and facilitators in COPD is not yet systematic. Future studies should be anchored in frameworks for sufficient comprehensiveness and facilitated knowledge translation into implementability.
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251070944, PROSPERO, CRD420251070944.
